Table 2.
Characteristics and biopsy assessment.
| Variables | Healthy | IgAN | N (IgAN) |
|---|---|---|---|
| N | 10 | 134 | 134 |
| Women, % | 90 **** | 31 | 134 |
| Age, year | 41 (39–42) ns | 43 (32–54) | 134 |
| sCr, mg/dL | NA | 1.7 (1.0–2.4) | 134 |
| eGFR, mL/min/1.73 m2 | NA | 46 (26–82) | 134 |
| PU, g/day | NA | 1.7 (0.8–3.2) | 131 |
| CRP, mg/L | NA | 2.5 (1.0–4.8) | 126 |
| CKD stage (1,2,3,4,5), % | NA | 19, 16, 31, 20, 13 | 134 |
| Level of fibrosis, % | NA | 30 (10–40) | 128 |
| Banff score (ci0, ci1, ci2, ci3), % | NA | 11, 34, 38, 17 | 133 |
| T-score (T0, T1, T2), % | NA | 45, 36, 19 | 130 |
| Hypertension a, % | NA | 64 | 134 |
| Diabetes b, % | NA | 8 | 134 |
Continuous variables are expressed as median (IQR) and categorial variables as %. Significant difference between the healthy and the IgAN groups was assessed with Mann–Whitney or chi-squared tests, where ns = not significant, and **** p < 0.0001 compared to IgAN. CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; NA, not available; PU, proteinuria; sCr, serum creatinine. a These patients had well-corrected hypertension. b These patients had well-compensated diabetes mellitus.